Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer: the Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) - Minckwitz, Gunter von; Rezai, Mahdi; Tesch, Hans; Huober, Jens; Gerber, Bernd; Zahm, Dirk M.; Hilfrich, Jörn; Costa, Serban Dan; Dubsky, Peter; Blohmer, Jens-Uwe; Denkert, Carsten; Hanusch, Claus Alexander; et al. (The European journal of cancer, 2016)